Search This Blog

Monday, April 27, 2026

CorMedix positive Phase III ReSPECT topline results for allogeneic HSCT patients

 

CorMedix reports positive Phase III ReSPECT topline results as REZZAYO meets primary endpoint in prophylaxis for allogeneic HSCT patients

  • Trial evaluated REZZAYO for prophylaxis of invasive fungal diseases in allogeneic HSCT patients
  • CorMedix plans an sNDA submission to the FDA for REZZAYO in 2H26
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)